Seven Eight Capital LP Grows Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Seven Eight Capital LP raised its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 12.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,665 shares of the life sciences company’s stock after acquiring an additional 4,584 shares during the quarter. Seven Eight Capital LP’s holdings in Integra LifeSciences were worth $1,477,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Champlain Investment Partners LLC increased its position in Integra LifeSciences by 10.3% during the first quarter. Champlain Investment Partners LLC now owns 2,687,972 shares of the life sciences company’s stock worth $95,289,000 after buying an additional 252,015 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in Integra LifeSciences by 18.6% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 81,614 shares of the life sciences company’s stock worth $2,893,000 after purchasing an additional 12,777 shares in the last quarter. Russell Investments Group Ltd. increased its position in Integra LifeSciences by 8.0% during the 1st quarter. Russell Investments Group Ltd. now owns 50,502 shares of the life sciences company’s stock worth $1,790,000 after purchasing an additional 3,743 shares in the last quarter. Headlands Technologies LLC raised its stake in Integra LifeSciences by 54.3% in the 1st quarter. Headlands Technologies LLC now owns 4,764 shares of the life sciences company’s stock valued at $169,000 after purchasing an additional 1,677 shares during the last quarter. Finally, Inspire Investing LLC lifted its holdings in Integra LifeSciences by 14.8% in the 1st quarter. Inspire Investing LLC now owns 10,143 shares of the life sciences company’s stock valued at $360,000 after purchasing an additional 1,311 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on IART shares. JMP Securities cut their price objective on shares of Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 7th. Citigroup increased their price target on Integra LifeSciences from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 10th. Truist Financial lifted their price objective on Integra LifeSciences from $25.00 to $32.00 and gave the company a “hold” rating in a research report on Tuesday, July 16th. StockNews.com downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. Finally, Oppenheimer cut Integra LifeSciences from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 7th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Integra LifeSciences currently has an average rating of “Hold” and a consensus price target of $32.86.

Integra LifeSciences Trading Up 0.2 %

NASDAQ:IART traded up $0.05 on Wednesday, hitting $31.42. 595,345 shares of the stock were exchanged, compared to its average volume of 1,086,449. The stock has a fifty day moving average of $29.49 and a 200-day moving average of $34.03. The stock has a market cap of $2.48 billion, a PE ratio of 62.74, a PEG ratio of 1.14 and a beta of 1.11. The company has a current ratio of 4.68, a quick ratio of 3.35 and a debt-to-equity ratio of 1.15. Integra LifeSciences Holdings Co. has a fifty-two week low of $22.36 and a fifty-two week high of $46.75.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, May 6th. The life sciences company reported $0.55 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.55. The firm had revenue of $368.90 million during the quarter, compared to the consensus estimate of $361.96 million. Integra LifeSciences had a net margin of 2.63% and a return on equity of 14.27%. The company’s revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.74 EPS. As a group, equities analysts expect that Integra LifeSciences Holdings Co. will post 3.03 earnings per share for the current fiscal year.

Insider Activity

In other Integra LifeSciences news, Chairman Stuart Essig purchased 52,641 shares of the firm’s stock in a transaction that occurred on Thursday, May 23rd. The stock was purchased at an average cost of $28.49 per share, with a total value of $1,499,742.09. Following the transaction, the chairman now owns 487,922 shares in the company, valued at $13,900,897.78. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.10% of the company’s stock.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.